Document Detail


Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension.
MedLine Citation:
PMID:  22185711     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Distal-type chronic thromboembolic pulmonary hypertension (CTEPH) is a fatal disease for which a new therapeutic strategy needs to be developed. We examined the effects of percutaneous transluminal pulmonary angioplasty (PTPA).
METHODS AND RESULTS: We prospectively enrolled 12 patients with distal-type CTEPH. After stabilizing their condition with pulmonary vasodilators, we then performed PTPA, which markedly improved pulmonary hemodynamics and pulmonary artery structure, as confirmed by angiography and optical coherence tomography, and also significantly improved their long-term prognosis compared with 39 historical controls.
CONCLUSIONS: PTPA is a promising therapeutic option for distal-type CTEPH.
Authors:
Koichiro Sugimura; Yoshihiro Fukumoto; Kimio Satoh; Kotaro Nochioka; Yutaka Miura; Tatsuo Aoki; Shunsuke Tatebe; Saori Miyamichi-Yamamoto; Hiroaki Shimokawa
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-12-15
Journal Detail:
Title:  Circulation journal : official journal of the Japanese Circulation Society     Volume:  76     ISSN:  1347-4820     ISO Abbreviation:  Circ. J.     Publication Date:  2012  
Date Detail:
Created Date:  2012-01-26     Completed Date:  2012-05-29     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  101137683     Medline TA:  Circ J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  485-8     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angioplasty / methods*
Antihypertensive Agents / therapeutic use
Chronic Disease
Combined Modality Therapy
Epoprostenol / analogs & derivatives,  therapeutic use
Female
Humans
Hypertension, Pulmonary / drug therapy,  physiopathology*,  therapy*
Male
Middle Aged
Piperazines / therapeutic use
Prognosis
Prospective Studies
Pulmonary Circulation / drug effects,  physiology*
Purines / therapeutic use
Sulfonamides / therapeutic use
Sulfones / therapeutic use
Treatment Outcome
Vasodilator Agents / therapeutic use
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Piperazines; 0/Purines; 0/Sulfonamides; 0/Sulfones; 0/Vasodilator Agents; 35121-78-9/Epoprostenol; 35E3NJJ4O6/beraprost; 3M7OB98Y7H/sildenafil; Q326023R30/bosentan
Comments/Corrections
Comment In:
Circ J. 2012;76(2):307-8   [PMID:  22240603 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Postischemic Myocardial Stunning Is Superior to Transient Ischemic Dilation for Detecting Multivesse...
Next Document:  Anticoagulation Control Quality Affects the D-Dimer Levels of Atrial Fibrillation Patients.